2014 SBIR Impact Companies

Cycle 3 Companies

1MM (One Million Metrics)
1MM is an industrial analytics company that performs real-time lifting metrics of material handling workers to reduce injuries and improve risk prevention.


Clarapath provides comprehensive histopathology services, which includes sectioning, staining, and slide imaging. The company seeks to transform clinical pathology through a combination of automated, high-definition “tissue-to-bits” histopathology techniques and a proprietary diagnostic & decision support software platform.

Innnovative Neurons

Innovative Neurons LLC, is a developer of medical device technologies – Med-Tech wearables and mobile health app solutions. The company is developing a multi-needle safety syringe as a market entry product.


Klincis assists healthcare organizations in realizing their desired state with respect to process, performance, and technology with the help of data. We provide technology enablement and change management consulting. Our secure, cloud-based decision-support applications help shape best practices. Our flagship application, Hēmcis, is a clinical protocol-based, secure decision support system that helps shape clinical best practices in the field of blood transfusions. Coupled with our business insights and performance management consulting, we connect the dots—lack of reimbursement, hospital payments, excess resource utilization—and give clinical and economic results so institutions can concentrate on patient care.


Mirna Analytics provides personalized service to researchers in medicine and veterinary medicine for the measurement of microRNA in body fluids, particularly plasma or sputum. MicroRNAs are small molecules made for short- and long-distance communication between cells. The concentration of these microRNAs in body fluids can indicate risk or protection from disease, and some microRNAs are also useful as disease markers. MicroRNAs are highly similar between species, including humans, pets, and agricultural animals.


SIPPA Solutions addresses the problem of fragmented health records that prevents the optimal interactions between an individual and the care providers. SIPPA Health is a technology stack that provides end-to-end solutions to facilitate secure and private health data exchange in a patient-centric model to reduce health record fragmentation, and to synchronize data in fragmented records with an ultimate goal of transforming health data into actionable information for meaningful use leading to better care quality outcome.

Urgent Consult_Logo for vendors

Urgent Consult is an automated online platform that streamlines the patient referral process. The platform helps hospitals keep referrals in-network and generate more revenue. A provider is able to base referrals on the patient’s convenience and the network affiliation, quality, and cost of the Specialist. Urgent Consult helps providers coordinate care across EMRs and care settings to improve patient healthcare outcomes.

Cycle 2 Companies

Aggamin logo

Aggamin is a bio-medical company founded by a scientific and business team in early 2010 to develop and commercialize therapies for a variety of diseases. The lead program is focused on preeclampsia — a currently untreatable disease affecting 10% of pregnancies with an annual cost to the U.S healthcare system of $7 billion. The company employs technologies in an innovative, proprietary, low-risk platform strategy to accelerate the drug development path with the goal of rapidly developing therapies to proprietary targets to improve patient health and quality of life.


ARL Designs develops high performance, low-cost superhydrophobic surfaces for biomedical devices.  By tailoring the surface chemistry and topography, ARL Designs surfaces can exhibit a range of properties including optical transparency and self-cleaning abilities.  Microliter quantities of fluids are easily manipulated and concentrated on the surfaces, enabling detection of targeted biomolecules for point-of-care diagnostic devices.


GeneticaLens, a company with more than 15 years of experience in video documentation and education about rare and difficult to diagnose disorders in young children, has developed an interactive, electronic toolkit, Well Child Lens (WCL). For use by parents and professionals, the toolkit is intended to reduce identified barriers to Autism Spectrum Disorder (ASD) surveillance and screening and to improve the accuracy of the screener with video enhancement.

L.A. Bruell Logo for SBIR Impact

L.A. Bruell, Inc. produces multi-platform training tools for healthcare professionals and the public. Founded in 1986 by Lucy Bruell, a journalist and instructor at the NYU School of Medicine, L.A. Bruell maintains many strategic alliances in the healthcare space, including the American Academy of Pediatrics, Weill Cornell School of Medicine, and the NYU School of Medicine. L.A. Bruell is a current recipient of an SBIR grant from the NICHD.


Lumidyne Technologies is focused on the synthesis and commercialization of next-generation fluorescent probes with enhanced photostabilty spanning the visible spectrum.  These dyes are 50-100% brighter and last over 100 times longer than commercially available dyes.  Their unique chemistries and synthetic strategies allow Lumidyne to tailor its products for a wide array of fluorescent-based applications ranging from cellular imaging to microarrays and genomic sequencing.


New York R&D Center for Translational Medicine and Therapeutics, Inc. is a company focused on the R&D and commercialization of new nutraceutical drugs for the prevention and treatment of osteoarthritis (OA).  Through a targeting screening process, based on a new set of OA pathogenic biomarkers, the company has developed a novel formulation of nutraceuticals which effectively slow OA disease progression, relieve OA-related joint pain, improve joint function, and is non-toxic.

Oncostem Biotherapeutics Logo

Oncostem Biotherapeutics, LLC., is a cancer drug discovery company with the goal of expanding the scope of personalized medicine by developing first-in-class inhibitors of oncogenic drivers.  The company has developed a proprietary algorithm that enabling prioritization of the selection of targets for drug inhibition. Oncostem Biotherapeutics was established by Rudolph E. Willis, M.D., a globally renowned oncologist, and Scott M. Kahn, Ph.D., an expert in oncology, cellular signaling and translational research, and a pioneer in the field of oncogene addiction.


SolveBio delivers the critical reference data used by hospitals and companies to run genomic applications. These applications use SolveBio’s data to predict the effects of slight DNA variants on a person’s health. SolveBio has designed a secure platform for the robust delivery of complex reference datasets. The company makes the data easy to access so that our customers can focus on building clinical grade molecular diagnostics applications, faster.


Cycle 1 Companies

Ex Vivo Dynamics is developing a non-invasive platform technology to reduce serious complications from blood transfusions.


Girihlet is bringing to market a new technology to sequence mitochondrial DNA, to analyze variations and modifications of the mtDNA genome and to correlate it with clinical outcomes in cancer and development. Girihlet’s overarching goal is to take genomics beyond the usual by use of ingenious techniques in the lab and computational algorithms. The aim is to have a significant impact in the clinic and help advance basic research by developing useful tools.

Immunovent is a NYC-based bioventure focused on commercialization of novel technologies for diagnosing allergies.  The company is currently developing the Local Allergy Mucosal Brush (LAMB) Test, a technology that emerged from research at the Weill-Cornell College of Medicine.  The LAMB test is the first local allergy test that can conveniently and accurately diagnose the ~25% of respiratory and food sensitivities that fail to be detected by traditional skin- and blood-based allergy testing.


Oculogica Inc. is a neuro-diagnostics company focusing on brain injury. The company’s proprietary EyeBoxCNS eye-tracking technology is able to measure the extent of neurological damage caused by concussion and other brain injuries simply by tracking eye movements as a subject watches TV for 220 seconds. The test is objective, automatic, non-invasive and does not require a baseline.  It can be used to streamline care in the Emergency Room as well as assess recovery.  It is currently being trialed at four clinical locations in NYC and Philadelphia. Newsweek article